Home › Transthyretin-Related Hereditary Amyloidosis
Transthyretin-Related Hereditary Amyloidosis clinical trials recruiting in the U.S.
9 studies for Transthyretin-Related Hereditary Amyloidosis are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY5 studies
- Los Angeles, CA5 studies
- Boston, MA4 studies
- Durham, NC4 studies
- Dallas, TX4 studies
- Baltimore, MD4 studies
- San Diego, CA4 studies
- Philadelphia, PA4 studies
- Portland, OR4 studies
- Kansas City, MO3 studies
- Washington, DC3 studies
- Houston, TX3 studies
- Rochester, MN3 studies
- St. Louis, MO3 studies
- Chicago, IL3 studies
- Richmond, VA3 studies
- New Haven, CT3 studies
- Jacksonville, FL3 studies
- Cleveland, OH3 studies
By state
- California5 studies
- Connecticut3 studies
- District of Columbia3 studies
- Florida3 studies
- Illinois3 studies
- Maryland4 studies
- Massachusetts4 studies
- Minnesota3 studies
- Missouri4 studies
- New York5 studies
- North Carolina4 studies
- Ohio4 studies
- Oregon4 studies
- Pennsylvania4 studies
- South Carolina3 studies
- Texas5 studies
- Virginia3 studies
Recently updated studies
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT06465810Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07654855ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
RecruitingObservational study
All ages · All sexes · Updated Sep 8, 2026 · NCT04561518Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Recruiting
Ages 65 and older · All sexes · Updated Sep 1, 2026 · NCT05577819Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
RecruitingObservational study
Ages 30 to 80 · All sexes · Updated Aug 31, 2026 · NCT05489549Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Jul 29, 2026 · NCT07695701Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RecruitingPhase 2
Ages 40 to 90 · All sexes · Updated Apr 13, 2026 · NCT05758493MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
RecruitingPhase 3
Ages 18 to 90 · All sexes · Updated Mar 27, 2026 · NCT06128629From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.